Deciphering Preserved Autonomic Function After Multiple Sclerosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorMayo Clinic

About this trial

This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.

Eligibility criteria

Qualifiers

18-50 years old

clinically confirmed diagnosis of multiple sclerosis -OR- uninjured control

Disqualifiers

symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment)

women who are pregnant or lactating

having a body mass index (BMI) ≥ 35 kg/m2

taking or being administered a medication known to potentially have adverse interactions with phenylephrine

Trial design

Treatments tested in this trial

  • Tests of sympathetic inhibition
  • Tests of sympathetic activation
  • Testing of autonomic dysreflexia

Treatment groups

13 Participants
are divided into 2 treatment groups

Sponsors and collaborators